British drugmaker GSK said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main ...

Everything we covered on WTR over the past seven days, and all you need to know from the world of trademarks to set yourself up for the start of another busy week.

GlaxoSmithKline (GSK) has accelerated the review of its Horlicks business in India, hoping to sell it for over $4 billion and potentially use the cash for Novartis' buy out deal. Bloomberg ...

The payment was made for the merger of GSK’s India brands with HUL, including Horlicks, Boost, Maltova, and Viva. The company said the demand will not have any significant financial implications ...

Stocks like Mankind Pharma, Indian Energy Exchange, NHPC, BGR Energy Systems, PDS, Jindal Stainless, and Medi Assist ...

In Dec 2018, HUL announced the merger of GSK Consumer Healthcare with the company. Under the terms of the merger deal, which was completed in 2020, HUL acquired the Horlicks brand for India from ...

Notably, the notification concerns the acquisition of the Horlicks brand for India from GSK for Rs 3,045 crore. This transaction also brought other GSKCH products into HUL’s portfolio ...

As one of the fastest-growing major economies in the world, India has recorded a GDP growth of 7.6%* in FY 2023-24, owing to a strong rebound in economic activity. Rising disposable income levels ...

The Indian pharmaceuticals market continued to report mid-single-digit growth in August, as sales grew 6.3% annually, ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

including an interest of Rs 329.33 crore for the Rs 3,045-crore acquisition of the India Health Food Drink (HFD) business from the GlaxoSmithKline (GSK) Group, the FMCG major said on Tuesday.